Appointment Icon

UnityPoint Clinic - Express (Ankeny)

1055 Southwest Oralabor Road
Ankeny, IA 50023

04 Patients
Waiting Now

UnityPoint Clinic - Express (Jordan Creek)

180 Jordan Creek Pkwy
West Des Moines, IA 50266

10 Patients
Waiting Now

UnityPoint Clinic - Express (Waukee)

950 E Hickman Rd
Waukee, IA 50263

06 Patients
Waiting Now

UnityPoint Clinic Behavioral Health Urgent Care - Des Moines

1250 East 9th Street
Des Moines, IA 50316

00 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Altoona

2720 8th Street Southwest
Altoona, IA 50009

05 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ankeny Medical Park

3625 North Ankeny Boulevard
Ankeny, IA 50023

04 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

2103 Ingersoll Avenue
Des Moines, IA 50312

14 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Merle Hay

4020 Merle Hay Road
Des Moines, IA 50310

05 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Southglen

6520 Southeast 14th Street
Des Moines, IA 50320

20 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Urbandale

5200 NW 100th Street
Urbandale, IA 50322

05 Patients
Waiting Now

Cutting Edge Precision Medicine Trial Available for Cancer Patients

by -

Precision medicine is likely the next big thing in cancer news. What is precision medicine? It’s a treatment approach that takes into account individual differences in people’s genes, environments, and lifestyles. Precision medicine gives clinicians tools to better understand the complex mechanisms underlying a patient’s health, disease, or condition, and to better predict which treatments will be most effective. Thanks to Iowa Oncology Research Association (IORA) and John Stoddard Cancer Center, patients no longer need to travel far from home to enroll in a large precision medicine trial. 

“If you look at two people with the same type and stage of cancer, why does one patient well and the other doesn’t?” asked Dr. Robert Behrens, local principal investigator of the study. “This study looks at treating patients based on the individuality of their tumor rather than simply their cancer type and stage.” 

IORA is taking part in the Molecular Analysis for Therapy Choice (MATCH) clinical trial. MATCH is a national precision medicine trial that explores treating patients based on the molecular profiles of their tumors.  MATCH is for adults with solid tumor and lymphomas that no longer respond to standard treatment. The trial opened for enrollment in August 2015 with 10 treatments, closed for an interim analysis, and has now re-opened with 24 treatments. Each treatment will enroll adults with advanced solid tumors and lymphomas that are no longer responding (or never responded) to standard therapy and have begun to grow. 

About 5,000 cancer patients will be screened with a tumor biopsy. The biopsied tumor tissue will undergo gene sequencing. Gene sequencing will look for changes in 143 genes. If a patient’s tumor has a genetic abnormality that matches one targeted by a drug used in the trial, the patient will be eligible to join the treatment portion of the MATCH trial. Not all patients will have tumors with an abnormality that matches a drug being tested. Patients with tumors that share the same genetic abnormality, regardless of tumor type, will receive the drug that targets that abnormality. The drugs included in the trial have all either been approved by the U.S. Food and Drug Administration (FDA) for another cancer indication or are still being tested in other clinical trials but have shown some effectiveness against tumors with a particular genetic alteration(s). 

Once enrolled, patients will be treated with the targeted drug for as long as their tumor shrinks or remains stable. The trial covers the cost of the biopsy and molecular tests, and patients will receive the drugs without charge if they are eligible to enroll for an NCI-MATCH treatment.

Do you have cancer that has returned or gotten worse after standard treatment, or has no standard treatment? If so, consider asking your doctor about this study. Visit for more information.